Question · asked by 1 review

Summary of findings ‐ ivacaftor vs placebo: QoL

Population
adults and children with cystic fibrosis and with at least one R117H CFTR mutation
Intervention
Summary of findings ‐ ivacaftor
Comparison
placebo
Outcome
QoL

The review found no eligible studies for this question.

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Summary of findings ‐ ivacaftor vs placebo
QoL Total score · adults and children with cystic fibrosis and with at least one R117H CFTR mutation
The review found no eligible studies for this question.
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (2019) · Cochrane Headline outcomes only
no estimate extractedNot reportedNo studies found

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis
2019 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.